LMI Cofator de Ristocetina BioFlash Jornal

8/13/2019 LMI Cofator de Ristocetina BioFlash Jornal

1/2

Vol.30 No.4 6-7/2013ISSN 1068-1760

Prostate Cancer TestCloser to Clinical Trial

AAbreakthrough urine biomarker forprostate cancer will soon be avail-

able which will signal a significant stepforward in the battle against prostatecancer. A protein called Engrailed-2(EN2) is made by prostate cancers andsecreted into urine where it can easilybe detected in a small urine sample

Contd on page 4

Novel Biomarker DetectsDeadly Lymphoma

AAnovel diagnostic test accuratelyidentifies patients who have a

new type of deadly intestinal lym-phoma that is particularly common inAsia. The test will have an immediateimpact on patient care, with doctorsnow able to diagnose patients accurate-ly and tailor more effective treatment

Contd on page 8

W O R L D S C L I N I C A L L A B O R A T O R Y N E W S L E A D E R

R E A D E R S E R V I C E P O R T A L

LINKXPRESS COM

V I S I T

If your subscriptionis not renewed every 12 monthsyour Free Subscription may be

automatically discontinued

Identify LinkXpress codes ofinterest as you read magazine

Click on LinkXpress.comto reach reader service portal

Mark code(s) of interest onLinkXpress inquiry matrix

Renew/Start yourFree Subscription

Access InteractiveDigital Magazine

Instant OnlineProduct Information:

1

2

3

PPhysicians will have access to anew noninvasive prenatal test,

which uses cell-free fetal DNA incirculating maternal blood.

The test, called Panorama, usescell-free fetal DNA in circulatingmaternal blood to screen for chro-mosomal abnormalities associatedwith trisomy 21 (Down syndrome),

trisomy 18 (Edwards syndrome), tri-somy 13 (Patau syndrome) andmonosomy X (Turner syndrome).Panorama can be used as early asthe ninth week of pregnancy.

In December 2012, the AmericanCongress of Obstetricians and Gyne-cologists (ACOG) issued a medicalopinion stating that cell-free fetal

Noninvasive Prenatal Test ScreensBlood for Chromosomal Abnormalities

DAILY CLINICAL LAB NEWS

V I S I T

Rapid Molecular Testfor Chikungunya Virus

AAnovel molecular diagnosplatform with high sensitiv

and specificity has been developfor the early detection of the Ckungunya virus(CHIKV).

Chikungunya has reemerged an important arboviral infectionglobal health significance abecause of lack of a vaccine a

Process Offers Potentia

for New BiomarkersAA

cutting-edge technology hbeen developed that can s

cessfully screen human blood disease markers that may hold tkey to better diagnosing and undstanding of puzzling health contions, including autoimmune deases. The technology accuratidentified human blood markers

Contd on pag

Contd on pag

Blood Test TracksResponse to CancerTreatment

Blood Test TracksResponse to CancerTreatment

Image: A cluster of breast cancercells showing visual evidence of

programmed cell death

Image: A cluster of breast cancercells showing visual evidence of

programmed cell deathSee article on page 13

A blood test that tracksfragments of DNA shedby dying tumor cells couldbe used to monitor how wellpatients are responding tocancer treatment, as well asprovide a non-invasive al-ternative to biopsies in ad-

vanced breast cancer.

Contd on page 6 Contd on page 33

Diagnostic Blood Test forFibromyalgia Developed

CCytokine-producing activity ofimmune cells of fibromyalgia

(FM) patients has led to the develop-ment of a commercial blood test.

The very real biological conditionof FM takes an average of three tofive years for someone with the ill-ness to get an accurate diagnosis ashitherto there was no diagnostic

INSIDE

PUBLISHED IN COOPERATION

International Federationof Clinical Chemistry

and Laboratory Medicine

Clinical News . . . . . . .IFCC News . . . . . . . . .

EFLM Corner . . . . . . . .

Product News . . . . . 2

Technical Literature 58

Industry News . . . . . . .

International Calendar

GLOBETECH

MEDIA> > >

8/13/2019 LMI Cofator de Ristocetina BioFlash Jornal

2/2LabMedica International

June-July/2013

LabMedicaLabMedica

LabMedica lnternationalis published eight times and is circuIated worldwide (outside the USACanada) without charge and by written requeclinical laboratory specialists and administratorsother qualified professionals allied to the field.

To all others: Paid Subscription is available for ayear subscription charge of US$240. Single copyis US$20. Mail your paid subscription order acco

nied with payment to Globetech Media, P.O.B. 80Miami, FL 33280-2214.

For change of address or questions on yourscription, write to:LabMedicalnternational, Circulation Ser-vices at above address; orvisit: www.LinkXpress.com

Vol.30 No.4. Published, under license, by Globetech LLC; Copyright 2013. All rights reserved. Reproducany form is forbidden without express permission. Opexpressed are solely those of the authors, and do nresent an endorsement, or lack thereof, by the Publisany products or services.

ADVERTISING SALES OFFICES

HOW TO CONTACT US

ISSN 1068-1760

SUBSCRIPTION INFORMATION

labmedica.com

EDITORIAL BOARD

Rosa I. Sierra-Amor Mexico

Claus Christiansen Denmark

Bernard Gouget France

Jocelyn M. Hicks United States

Anders Kallner Sweden

Christopher Price United Kingdom

Andreas Rothstein Colombia

Dmitry B. Saprygin Russia

Grard Siest France

Andrew Wootton United Kingdom

A GLOBETECH PUBLICAT

Published in cooperation with the International Fedeof Clinical Chemistry and Laboratory Medicine (IFCCEuropean Federation of Clinical Chemistry and LaboMedicine (EFLM).

HospiMedica International HospiMedica en Espaol HospiMedLabMedica International LabMedica en Espaol LabMediMedical Imaging International Bio Research International MedimHospiMedica.com LabMedica.com BiotechDaily.com Trade

USA P.O.Box 800806, Miam i, FL 33280, U

[email protected] Tel: (1) 954-893-0

GERMANY, SWITZ., AUSTRIA Bad Neustadt, Germ

Jut ta .C io [email protected] Te l: (49) 9771-3

UK, FRANCE, NORDIC REG. Gerrards Cross

Paul.Mi [email protected] Tel: (44) 1753-892

ITALY Genoa,


JAPAN Tokyo, Ja


CHINA Shenzen, Guangdong, C


ALL OTHER COUNTRIES Contact USA O


Teknopress Yaynclk ve Ticaret Ltd. St i. adnaImtiyaz Sahibi: M. Geren Yaz isleri Mdr: Ersin Kk

Msi r Dervis Ibrahim So k. 5/4, Esent epe, 34394 Si sl i, Istanbul, TFaks: (212) 216-6997 P. K. 1, AVPIM, 34001 Istanbul

Bask: Promat Web Ofset Tesisi Sanayi Mahallesi 1673. SoNo: 34 34510 Esenyurt, B. ekmece Istanbul, Trkiye

Yerel sreli yayndr. Ylda sekiz kere yaynlanr, cretsiz dag

Dan Gueron

Jill Roberge

Jacqueline Miller, PhD

Raymond L Jacobson, PhD

Gerald Slutzky, PhD

Andreas Rothstein

Marcela Jensen

Joseph Ciprut

Brenda Silva

Paul MillsDoris Mendieta

Dr. Jutta Ciolek

Christina Chang

Arda Turac

Elif Erkan

Subscriptions:Send Press Releases to:

Advertising & Ad Material:Other Contacts:

PublisherEditorial DirectorNews DirectorNews EditorNews EditorNews EditorAssistant EditorAssistant EditorNew Products Edito

Regional DirectorRegional DirectorRegional DirectorRegional DirectorProduction DirectorReader Service Ma

www.LinkXpress.coLMNews@[email protected]@globetech.net

AAfully automated von Willebrand Factor assay hasbeen released in Europe and international territories

as a European CE in vitro diagnostic (IVD) Mark productunder the European Directive on in vitro DiagnosticMedical Devices but not currently [US FDA] 510(k)cleared. A product of Instrumentation Laboratories(Bedford, MA, USA; www.instrumentationlaboratory.com/ilww), the fully automated HemosIL AcuStar VWFassay panel, designed exclusively for use on the ACLAcuStar Hemostasis Testing System, includes HemosILAcuStar VWF Antigen (VWF:Ag) and HemosIL AcuStarVWF Ristocetin Cofactor (VWF:RCo) Activity assays.

HemosIL AcuStar VWF:RCo is the first fully automat-

ed, chemiluminescent assay to use recombinant technol-ogy, allowing full automation and greater precision thanplatelet-based tests. It meets guidelines on VDF investiga-tion and enhances accuracy versus manual methods.Chemiluminescence offers an enhanced linearity range toquantify extremely low levels of VWF concentrations.

Like all reagents on the ACL AcuStar System,HemosIL AcuStar VWF assays are ready-to-use, car-tridge-based and offer results in 30 minutes on-demand, 24/7. This is the third specialty assay panel

commercialized on the ACL AcuStar system. Previouslyintroduced panels include Antiphospholipid Syndromeand Heparin-Induced Thrombocytopenia.

With the ACL AcuStar Hemostasis Testing System,our goal is to automate complex assays and offerenhanced efficiency and sensitivity where it mattersmost, said Remo Tazzi, Director of HemostasisMarketing at IL. Our new HemosIL AcuStar VWFassays achieve this, allowing clinicians to make quickerand more effective patient care decisions.

VDF is an acquired or inherited bleeding disorder,caused by a qualitative or quantitative defect of theVWF protein. Whereas hemophilia mainly affects

males, VDF is not gender-specific. The disease affectsover 1% of the worldwide population and occurs in1/100100,000 people with hemophilia. AcquiredVDF can be associated with serious autoimmune prob-lems (e.g., rheumatoid arthritis, systemic lupus erythe-matosus, and specific types of kidney failure or cancers)and may develop with no underlying conditions.Certain kinds of VDF may remain undiagnosed becausesymptoms can be mild. Prompt diagnosis and classifica-tion are necessary for optimal therapeutic management.

Fully-Automated von Willebrand Factor Assay Panel Released

contd from cover

from men, allowing faster testing that could save lives

and offer the potential for huge cost savings. TheUniversity of Surrey (Guildford, UK; www.surrey.ac.uk)where the test was originally developed has signed aworldwide nonexclusive agreement with internationaldiagnostic specialist Zeus Scientific (Raritan, NJ, USA;www.zeusscientific.com) to develop and market itsbreakthrough urine biomarker, EN2. Urinary EN2 lev-els can be measured by an enzyme-linked immunosor-bent assay and higher EN2 levels correlated with thestage of the tumor.

In a joint statement, the University and the ProstateProject Charity (Godalming, UK; www.prostate-project.org.uk) who jointly funded the research, said: This isthe news we have all been waiting for. In two years ofextensive trials in the USA and Europe, EN2 has consis-

tently outperformed the 30-year-old prostate-specificantigen (PSA) test proving itself to be twice as effective

at finding prostate cancer. Its accuracy has never been indoubt, but it has proved difficult to bulk test urine sam-ples using conventional assay technology. Now, ZeusScientific, one of the leaders in this field is confident itcan overcome the problems and bring EN2 to market.

Hardev Pandha MD, PhD, professor of MedicalOncology at the University of Surrey, said, TheUniversity of Surrey is looking forward very much toworking with Zeus to introduce EN2 as a novel diag-nostic test for prostate and bladder cancers. Our testshave shown that levels of EN2 correlate strongly withdisease volume. Knowledge of disease volume mayhelp urologists assess whether the patient has a smallvolume of disease that may be safely and actively mon-itored or a larger volume that needs to be treated.

Prostate Cancer Test Closer to Clinical Trial

contd from cover

neuromyelitis optica (NMO), a rare autoimmune dis-order resembling multiple sclerosis that can result inblindness and paralysis, by substituting antibody-binding targets with biologically unnatural moleculescalled peptoids.

Scientists at Scripps Research Institute (Jupiter,FL, USA; www.scripps.edu) identified several pep-toids that bound exclusively to antibodies in NMO

patient blood serum and not healthy patients orpatients with similar diseases, including multiplesclerosis (MS), lupus, Alzheimers disease (AD) andnarcolepsy. At least one of the peptoids bound to anantibody that is well known to be associated withNMO.

The team used the chemical library screeningtechnology to identify a synthetic peptoid thatbinds anti-Aquaporin 4 (AQP4) antibodies in theserum of NMO patients. After processing theserum, slides were scanned on a GenePix 4200ALmicroarray scanner (Molecular Devices;

Sunnyvale, CA, USA; www.moleculardevices.com)by using the 488/635 nm laser at 100% power anda 500-photomultiplier-tube gain.

The investigators screened 100,000 peptoids usinga second-generation bead-based screening approachthat yielded several peptoid ligands for the antigen-binding site of anti-AQP4 antibodies. They showed ina small preliminary study that the use of a small panelof these peptoids allows one to distinguish between

NMO patient serum and serum from healthy controlsor patients with MS, AD, narcolepsy, and lupus withhigh accuracy.

Thomas Kodadek, PhD, the senior author of thestudy, said, We find disease biomarkers differentlythan anyone else. This enables new disease biomark-er detection. Additionally, by using these peptoid hitsto fish for disease-specific antibodies, the systemenables disease-specific antibody detection withoutfirst knowing the antibodies natural binding targets.The study was published on March 21, 2013, in thejournal Chemistry & Biology.

Process Offers Potential for New Biomarkers

LMI Cofator de Ristocetina BioFlash Jornal

Documents

Transcript of LMI Cofator de Ristocetina BioFlash Jornal